Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Target Market Determination – Broker Offer

April 17, 2025April 17, 2025 Alterity Therapeutics

TMD – Broker Offer

Post navigation

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Target Market Determination – Placement Offer

Related Posts

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

April 10, 2024March 10, 2025

Prana Provides Update on PBT2 Alzheimer’s Disease Extension trial

December 12, 2013August 16, 2022

Prana Provides Huntington Disease Trial Update in conjunction with the Huntington Study Group Annual Conference

July 17, 2013August 16, 2022

Recent Posts

Alterity Therapeutics Prominently Featured at the International MSA Congress
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065